Better Therapeutics, Inc. (BTTX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Dec 26, 2024, 4:00 PM EST

Better Therapeutics Company Description

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases.

The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes.

It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.

In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease.

Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease.

The company was founded in 2015 and is headquartered in San Francisco, California.

Better Therapeutics, Inc.
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 54
CEO Frank Karbe

Contact Details

Address:
548 Market Street
San Francisco, Delaware 94104
United States
Phone 415 887 2311
Website bettertx.com

Stock Details

Ticker Symbol BTTX
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
ISIN Number US08773T1043
SIC Code 7372

Key Executives

Name Position
Frank L. Karbe Chief Executive Officer, Interim Chief Financial Officer, President and Director
David P. Perry M.B.A. Co-Founder and Executive Chairman
Dr. Mark A. Berman M.D. Chief Medical Officer
Kristin Wynholds Chief Product Officer
Andres Camacho Senior Vice President of Technology and Head of Engineering
Angela Willis Senior Vice President of Market Access
Jessica Meng Chief Commercial Officer
Leslie Miller Controller